We are live on ! Find out more

bioAffinity Technologies

BIAF

Market cap $4.7M

7.83 USD

-0.11

1.39%

At close Updated Sep 24, 4:00 PM EDT

Pre-market

After hours

7.86

+0.03

0.38%

1 day

-1.39%

5 days

-26.55%

1 month

34.54%

3 months

-38.64%

6 months

-86.82%

Year to date

-57.21%

1 year

-87.83%

5 years

-99.79%

10 years

-99.79%

About: bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Employees: 57

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 10%

Neutral 85%

Negative 5%

bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.

bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

Shares of BioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Thursday afternoon following the grant of a key Hong Kong patent for its CyPath Lung diagnostic. The rally is also boosting BioAffinity's Warrants (NASDAQ:BIAFW), up nearly 20% late Thursday.

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.

bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements.

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?

Shares of bioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Wednesday morning as traders digest recent commercial expansion announcements alongside tight low-float trading dynamics.

BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?

bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies is advancing the application of its CyPath Lung test for surveillance of lung cancer patients who have completed treatment.

bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will effect a 1-for-15 reverse split of its common stock at the opening of trading on Nasdaq on August 24, 2026.

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock.

WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

See News Rankings

Price charts implemented using Lightweight Charts™